Monitoring for Late Effects

Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: General Information About Late Effects of Treatment for Childhood Cancer

Recognition of both acute and late modality–specific toxicity has motivated investigations evaluating the pathophysiology and prognostic factors for cancer treatment–related effects. Consequently, the results of late effects research have played an important role in the following areas:

Changing pediatric cancer therapeutic approaches to reduce treatment-related mortality among survivors treated in more recent eras.[47]

Source links and citations

The development of risk counseling and health screening recommendations for long-term survivors by identifying the clinical and treatment characteristics of those at highest risk of therapy-related complications.[48]

Source links and citations

The common late effects of pediatric cancer encompass several broad domains, including the following:

Growth and development.

Organ function.

Reproductive capacity and health of offspring.

Secondary carcinogenesis.

Psychosocial sequelae related to the primary cancer, its treatment, or maladjustment associated with the cancer experience.

Late sequelae of therapy for childhood cancer can be anticipated based on therapeutic exposures, but the magnitude of risk and the manifestations in an individual patient are influenced by numerous factors. Multiple factors should be considered in the risk assessment for a given late effect (see Figure 3).[49]

Source links and citations

Cancer-related factors:

Organs or tissues affected by the cancer.

Direct tissue effects.

Cancer-induced organ dysfunction or other tissue effects.

Treatment-related factors:

Radiation therapy: Total dose, fraction size, organ or tissue volume exposed.

Chemotherapy: Agent type, dose-intensity, cumulative dose, schedule.

Surgery: Technique, site, consequential organ dysfunction.

HSCT.

Combined-modality effects (therapeutic interactions).

Blood product transfusion.

Chronic graft-versus-host disease.

Host-related factors:

Sex.

Genetic predisposition.

Premorbid, comorbid, posttreatment health states and exposures.

Developmental status (age).

Time from diagnosis/therapy.

Inherent tissue sensitivities and capacity for normal tissue repair.

Hormonal milieu.

Socioeconomic status.

Health habits.

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice